The FDA on March 1, 2024, approved RYBREVANT® (Amivantamab-vmjw) with Carboplatin and Pemetrexed for the first-line treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. RYBREVANT® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
